Posted by Michael Wonder on 04 Jan 2020
NICE refuses Akcea’s Waylivra
3 January 2020 - NICE has issued an Evaluation Consultation Document, refusing Waylivra (volanesorsen) as a treatment for familial chylomicronaemia syndrome.
The document states that the drug isn’t recommended for use on the NHS, despite being “innovative and the only authorised treatment for familial chylomicronaemia syndrome”.
The draft negative guidance goes on to states that NICE has “concerns around the clinical evidence and high cost, and therefore did not consider it an appropriate use of NHS resources.”
